0000000001169931

AUTHOR

Berg Thomas

0000-0003-0003-6241

showing 1 related works from this author

The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients…

2008

Background/Aims The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown. Methods Nineteen patients with chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9 HCV-genotype 2 or 3) were included in this prospective multicenter pilot study. Baseline HBV-DNA was negative in 13 individuals. All patients received weight-adjusted PEG-IFN-α2b and ribavirin for 48 weeks. Results In the intent-to-treat analysis, a biochemical and an HCV-RNA response were observed in 12 and 14 patients, respectively (63% and 74%). At the end of the treatment as well as at the end of the follow-up the HCV-RNA response was 93% (14/15) in patients adher…

AdultMalemedicine.medical_specialtyHBsAgCombination therapyHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis B ChronicPegylated interferonInternal medicineRibavirinmedicineHumansProspective StudiesAdverse effectAgedHepatitis B virusHepatologybusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis C ChronicMiddle AgedRecombinant Proteinsdigestive system diseaseschemistryDNA ViralImmunologyRNA ViralFemaleViral diseasebusinessmedicine.drugJournal of Hepatology
researchProduct